-+ 0.00%
-+ 0.00%
-+ 0.00%

Shaanxi Micot says Phase II trial of MT200605 meets primary endpoint in acute ischemic stroke in China

PUBT·08/26/2026 14:39:23
Listen to the news
Shaanxi Micot says Phase II trial of MT200605 meets primary endpoint in acute ischemic stroke in China
  • Shaanxi Micot Pharmaceutical Technology reported completion of a Phase II China trial of MT200605 for acute ischemic stroke.
  • Results have already been presented via database lock in July 2026 and confirmation in August 2026 that the study met its main goal.
  • Trial outcomes indicated meaningful functional recovery benefits versus placebo, with earlier neurological improvement signals in the highest-dose group.
  • Safety profile was described as favorable, with findings suggesting reduced risk of kidney complications in stroke patients.
  • MT200605 is positioned as a potential neuroprotection and repair therapy, supporting a path toward later-stage development decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Micot Pharmaceutical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12301379), on August 26, 2026, and is solely responsible for the information contained therein.